Alerts will be sent to your verified email
Verify EmailDCAL
Dishman Carbogen Amc
|
Sun Pharma Adv. Res
|
Zenotech Laboratorie
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
US DMF Filings
|
18.0 . | n/a | n/a |
Total reactor capacity
|
1150.0 kL | n/a | n/a |
R&D as a % of Total Sales
|
1.64 % | 576.14 % | n/a |
Financials
|
|||
5 yr Average ROE
|
-1.15 % | -64.48 % | 7.83 % |
5yr average Equity Multiplier
|
1.61 | 1.39 | 1.26 |
5yr Average Asset Turnover Ratio
|
0.26 | 0.22 | 0.33 |
5yr Avg Net Profit Margin
|
-2.96 % | -361.01 % | -17.58 % |
Price to Book
|
0.81 | 0.0 | 3.34 |
P/E
|
45.15 | 0.0 | 60.96 |
5yr Avg Cash Conversion Cycle
|
24.66 Days | 80.33 Days | 36.89 Days |
Inventory Days
|
110.18 Days | 0.0 | 145.01 Days |
Days Receivable
|
77.38 Days | 80.33 Days | 61.38 Days |
Days Payable
|
156.95 Days | 0.0 | 477.06 Days |
5yr Average Interest Coverage Ratio
|
0.4 | -97.45 | -4.03 |
5yr Avg ROCE
|
0.91 % | 208.61 % | 7.95 % |
5yr Avg Operating Profit Margin
|
13.93 % | -357.39 % | 4.66 % |
5 yr average Debt to Equity
|
0.3 | -0.27 | 0.12 |
5yr CAGR Net Profit
|
n/a | 9.0 % | n/a |
5yr Average Return on Assets
|
-0.73 % | -68.32 % | 7.07 % |
Shareholdings
|
|||
Promoter Holding
|
59.32 % | 65.67 % | 68.84 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | -3.42 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
-5.47 % | 0.7 % | 0.0 |
Dishman Carbogen Amc
|
Sun Pharma Adv. Res
|
Zenotech Laboratorie
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|